R. 1. Cohen, S. Emery, P. Greenwald, M. Dougados, M. Furie et al., Rituximab for rheumatoid arthritis refractory to anti???tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks, Arthritis & Rheumatism, vol.64, issue.9, pp.2793-806, 2006.
DOI : 10.1002/art.22025

J. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-sosnowska, P. Emery et al., Efficacy of B-Cell???Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis, New England Journal of Medicine, vol.350, issue.25, pp.2572-81, 2004.
DOI : 10.1056/NEJMoa032534

S. Dass, A. Rawstron, E. Vital, K. Henshaw, D. Mcgonagle et al., Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis, Arthritis & Rheumatism, vol.46, issue.10, pp.2993-3002, 2008.
DOI : 10.1002/art.23902

M. Leandro, G. Cambridge, M. Ehrenstein, and J. Edwards, Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.52, issue.2, pp.613-633, 2006.
DOI : 10.1002/art.21617

M. Nakou, G. Katsikas, P. Sidiropoulos, G. Bertsias, E. Papadimitraki et al., Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response, Arthritis Research & Therapy, vol.11, issue.4, p.131, 2009.
DOI : 10.1186/ar2798

M. Rehnberg, S. Amu, A. Tarkowski, M. Bokarewa, and M. Brisslert, Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis, Arthritis Research & Therapy, vol.11, issue.4, p.123, 2009.
DOI : 10.1186/ar2789

P. Roll, A. Palanichamy, C. Kneitz, T. Dorner, and H. Tony, Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis, Arthritis & Rheumatism, vol.174, issue.8, pp.2377-86, 2006.
DOI : 10.1002/art.22019

J. Sellam, H. Hendel-chavez, S. Rouanet, K. Abbed, B. Combe et al., B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study, Arthritis & Rheumatism, vol.62, issue.Suppl, pp.933-941, 2011.
DOI : 10.1002/art.30233

L. Quartuccio, M. Fabris, S. Salvin, F. Atzeni, M. Saracco et al., Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis, Rheumatology, vol.48, issue.12, pp.1557-1566, 2009.
DOI : 10.1093/rheumatology/kep314

G. Cambridge, M. Leandro, J. Edwards, M. Ehrenstein, M. Salden et al., Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis, Arthritis & Rheumatism, vol.105, issue.8, pp.2146-54, 2003.
DOI : 10.1002/art.11181

J. Mélet, D. Mulleman, P. Goupille, B. Ribourtout, H. Watier et al., Rituximab-Induced T Cell Depletion in Patients With Rheumatoid Arthritis: Association With Clinical Response, Arthritis & Rheumatism, vol.58, issue.Suppl 1, pp.2783-90, 2013.
DOI : 10.1002/art.38107

S. Piantoni, M. Scarsi, A. Tincani, and P. Airo, Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab, Rheumatology International, vol.4, issue.9, pp.1571-1574, 2015.
DOI : 10.1007/s00296-015-3295-0

A. Van-gestel, M. Prevoo, M. Van-'t-hof, M. Van-rijswijk, L. Van-de-putte et al., Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, Arthritis & Rheumatism, vol.38, issue.1, pp.34-40, 1996.
DOI : 10.1002/art.1780390105

E. Keystone, S. Cohen, P. Emery, J. Kremer, M. Dougados et al., Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study, The Journal of Rheumatology, vol.39, issue.12, pp.2238-2284, 2012.
DOI : 10.3899/jrheum.120573

P. Roll, T. Dorner, and H. Tony, Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment, Arthritis & Rheumatism, vol.33, issue.6, pp.1566-75, 2008.
DOI : 10.1002/art.23473